Comgest Global Investors’s Novo Nordisk NVO Stock Holding History

Comgest Global Investors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,961	Closed	-$830K	–	61
2025 Q3	$830K	Sell	14,961 -25,801	-63%	-$1.51M	0.01%	60
2025 Q2	$2.81M	Hold	40,762	–	–	0.05%	54
2025 Q1	$2.83M	Sell	40,762 -6,136	-13%	-$507K	0.05%	54
2024 Q4	$4.03M	Hold	46,898	–	–	0.07%	49
2024 Q3	$5.58M	Sell	46,898 -856	-2%	-$114K	0.08%	47
2024 Q2	$6.82M	Sell	47,754 -6,334	-12%	-$839K	0.09%	48
2024 Q1	$6.94M	Sell	54,088 -7,240	-12%	-$862K	0.1%	50
2023 Q4	$6.34M	Hold	61,328	–	–	0.1%	46
2023 Q3	$5.58M	Sell	61,328 -8,478	-12%	-$747K	0.1%	47
2023 Q2	$5.65M	Sell	69,806 -19,964	-22%	-$1.63M	0.09%	49
2023 Q1	$7.14M	Buy	+89,770	New	+$6.37M	0.13%	44

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Comgest Global Investors's NVO Position: Q4 2025 in Review

Comgest Global Investors sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 14,961 shares — an estimated $830K sold.

Comgest Global Investors first reported a position in NVO in Q1 2023 and held it in 11 quarters. The position peaked at $7.14M in Q1 2023. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Comgest Global Investors reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Comgest Global Investors sold 14,961 Novo Nordisk shares in Q4 2025, an estimated $830K.
Comgest Global Investors first reported a position in Novo Nordisk in Q1 2023 and held it in 11 quarters.
Comgest Global Investors's Novo Nordisk position peaked at $7.14M in Q1 2023.
1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Comgest Global Investors's 13F filing for Q4 2025, filed 12 Feb 2026.